CPEX Pharmaceuticals, Inc.
http://www.cpexpharmaceuticals.com/home.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CPEX Pharmaceuticals, Inc.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.
Chinese Regulator Rejects Domestic PD-1/L1 Contender In Latest Tightening Signal
After nearly three years of regulatory review, Genor Biopharma’s geptanolimab has become the first domestically-developed anti-PD-1/L1 drug to experience a major regulatory setback within the overcrowded class in China. Over the intervening years since it was submitted for approval, the country’s regulator has moved to tighten review standards.
Global Top 10 Medtechs Swap Places After Latest Quarterlies
Abbott Laboratories moved above Medtronic in MAT medtech revenues, while Philips Healthcare and Stryker finished 2022 with strong quarters, and Roche dropped a few places.
Finance Watch: VC Round Extensions Attractive While Stock Market Wobbles
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Nasal
- Transdermal
-
Drug Delivery
- Other Names / Subsidiaries
-
- Footstar, Inc.
- FCB Holdings, Inc.
- Xstelos Holdings, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice